Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Poly(ADP-ribose) polymerase inhibitors (PARPi) are effective in germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers.
• Emerging evidence indicates PARPi's potential in cancers with DNA damage repair pathway deficiencies.

Purpose of the Study:

• To review preclinical data and clinical development of PARPi.
• To discuss the future application of PARPi in solid tumors beyond gBRCAm-associated cancers.
• To highlight the importance of understanding molecular abnormalities and identifying predictive biomarkers for expanded PARPi therapy.

Main Methods:

• Review of preclinical studies on PARPi.
• Analysis of ongoing phase I/II clinical trials involving PARPi as single agents or in combination therapy.
• Discussion of molecular mechanisms and biomarker strategies.

Main Results:

• PARPi demonstrate clinical activity in gBRCAm-associated breast and ovarian cancers.
• PARPi are under investigation for prostate, lung, endometrial, and pancreatic cancers with DNA repair defects.
• Several PARPi are in early-phase clinical trials for these solid tumors.

Conclusions:

• Expanding PARPi therapy to solid tumors beyond gBRCAm-associated breast and ovarian cancers requires further research.
• Identifying molecular abnormalities and predictive biomarkers is crucial for optimizing PARPi efficacy.
• Novel therapeutic strategies and drug combinations are essential for improving outcomes in advanced solid tumors treated with PARPi.